Relation between psychosis and nicotine
Reading File
Searching PubMed
nicotine psychosis schizophrenia
Finding Sources
Finding Sources
Searching PubMed
smoking tobacco psychosis risk first episode
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
I now have thorough content from three authoritative sources. Let me compile the comprehensive answer.
Psychosis and Nicotine: The Relationship
1. Epidemiology - How Common Is This?
The comorbidity is striking. Before vaping became widespread, 70-80% of people with schizophrenia regularly smoked cigarettes - roughly 2-3x the general population rate. Today, both tobacco and vaping remain extremely common in psychosis:
- A 2024 US study found 28% of people with first-episode psychosis used nicotine in some form, roughly double age-matched controls
- In longer-standing psychosis (2023 data), tobacco use was seen in just over 40%, but any nicotine product in 70-80% - essentially the same high prevalence as the pre-vaping era
- More broadly, ~40-50% of patients in psychopharmacology practices smoke, with 60-85% rates among those with schizophrenia, ADHD, and bipolar disorder
- Some estimates suggest more than half of all cigarettes consumed in the US are smoked by patients with a concurrent psychiatric disorder
(Maudsley Prescribing Guidelines, 15th ed.; Stahl's Essential Psychopharmacology)
2. The "Self-Medication" Hypothesis
Nicotine use in psychosis is not simply a bad habit - there is a strong self-medication rationale. People with psychotic disorders appear to use nicotine to:
- Relieve negative symptoms - Nicotine causes dopamine release (via nicotinic receptors on VTA dopaminergic neurons), reducing anhedonia and social withdrawal
- Counter antipsychotic side effects - Smoking alleviates antipsychotic-induced drowsiness, extrapyramidal side effects (EPSEs), and cognitive slowing
- Improve cognition - Nicotine improves concentration, vigilance, working memory, and attentional deficits - probably by enhancing glutamate, acetylcholine, and serotonin neurotransmission
- Fix auditory gating deficits - Schizophrenia patients have a well-documented deficit in auditory sensory gating (measured by the P50 event-related potential), and nicotine transiently corrects this, likely via α7 nicotinic receptor activation in the hippocampus
- Reduce antipsychotic-induced movement disorders - Smokers are less likely than non-smokers to develop drug-induced EPSEs and use anticholinergic drugs less often
- Structure daily activity - Behavioural/temporal fillering
(Maudsley Prescribing Guidelines, 15th ed., p. 933)
3. Neurobiological Mechanisms
Nicotinic Receptors and Dopamine
Nicotine is highly lipid-soluble and rapidly enters the brain after inhalation. It acts on nicotinic acetylcholine receptors (nAChRs), which are ligand-gated ion channels, through three overlapping pathways - as detailed in Stahl's:
- Direct dopamine release: Nicotine acts on α4β2 nAChRs on dopaminergic cell bodies in the ventral tegmental area (VTA), directly triggering dopamine release into the nucleus accumbens (mesolimbic reward pathway)
- Glutamate-mediated indirect pathway: Nicotine activates presynaptic nAChRs on glutamate neurons → glutamate release → dopamine release
- Disinhibition via GABA: Nicotine desensitizes α4β2 receptors on inhibitory GABAergic interneurons in the VTA → disinhibits dopamine neurons → further dopamine release in nucleus accumbens
The α7 Receptor and Cognition
The α7 nAChR on postsynaptic prefrontal cortex neurons is linked to nicotine's pro-cognitive and alerting effects - but NOT to addiction. This receptor subtype is of particular interest in schizophrenia because deficient α7 receptor function has been linked to auditory gating deficits and cognitive impairment. Nicotinic receptor agonists targeting α7 have been explored as pro-cognitive agents in schizophrenia (though none is yet licensed for this purpose).
(Stahl's Essential Psychopharmacology; Kaplan & Sadock's Comprehensive Textbook of Psychiatry)
4. Does Nicotine/Smoking Cause Psychosis?
This is an area of active debate. Key observations:
- The increased tendency to use nicotine predates the onset of psychiatric symptoms - it is not simply a consequence of illness or institutionalization
- Smoking might actually be a causal factor in schizophrenia - possibly through dopamine dysregulation (excess dopaminergic stimulation mirrors the hyperdopaminergia model of positive symptoms)
- There is also a familial vulnerability hypothesis - shared genetic factors may predispose both to smoking and to psychosis, rather than a direct causal link
(Maudsley Prescribing Guidelines, 15th ed., p. 933, references 13-14)
5. Nicotine, Antipsychotics, and Drug Interactions
This is clinically very important. Tobacco smoke (specifically polycyclic hydrocarbons, NOT nicotine itself) powerfully induces CYP1A2, the main enzyme metabolizing many antipsychotics. This can lower blood levels of affected drugs by more than 50%.
Drugs most affected:
| Drug | Effect of Smoking |
|---|---|
| Clozapine | Levels fall >50%; dose must be raised |
| Olanzapine | Significant reduction |
| Haloperidol, fluphenazine, chlorpromazine | Reduced levels |
| Tricyclic antidepressants, mirtazapine, fluvoxamine | Reduced levels |
Critical clinical point: If a patient on clozapine or olanzapine stops smoking (e.g., during hospitalization), CYP1A2 induction reverses and drug levels can rise sharply - potentially causing toxicity. Dose reduction on smoking cessation is often needed. Importantly, vaping does NOT affect hepatic enzyme function because it lacks the polycyclic hydrocarbons of tobacco smoke.
Also notable: the greater the D2 receptor occupancy by antipsychotics, the more likely the patient is to smoke. Conversely, patients on clozapine (a relatively weak D2 antagonist) find smoking cessation more achievable than those on conventional antipsychotics.
(Maudsley Prescribing Guidelines, 15th ed., pp. 933-934)
6. Smoking Cessation in Psychosis - Clinical Considerations
Managing smoking cessation in psychosis is complex:
- People with schizophrenia find it particularly difficult to tolerate nicotine withdrawal, which can exacerbate schizophrenia symptoms directly
- Nicotine withdrawal can be misdiagnosed as depression, anxiety, sleep disorders, or mania
- Switching to vaping/NRT is often preferred over abrupt cessation
- A switch from tobacco to vaping has been shown to be well tolerated even in severe mental illness
- Varenicline (a partial α4β2 agonist, used for smoking cessation) does NOT significantly increase neuropsychiatric adverse events (including anxiety, depression, aggression, psychosis, or suicidal behaviour) compared to placebo or nicotine patches - whether or not the patient has a pre-existing psychiatric disorder. This 2021 systematic review (PMID 33863511) also covered e-cigarette contributions in patients with psychotic disorders.
(Maudsley Prescribing Guidelines, 15th ed., pp. 934-935)
7. Other Psychiatric Conditions
| Condition | Nicotine Relationship |
|---|---|
| Depression/Anxiety | Moderate nicotine causes pleasure and decreases anxiety; withdrawal can precipitate/exacerbate depression; stopping smoking ultimately may improve mood |
| ADHD | Higher smoking rates (twice normal); nicotine self-medicates ADHD via dopamine/arousal enhancement; tobacco smoke MAO inhibitors may also benefit ADHD |
| Parkinson's disease | Nicotine is protective - increases dopaminergic neurotransmission, delays onset; smokers also less vulnerable to drug-induced EPSEs |
| Bipolar disorder | High smoking rates (60-85% in psychopharmacology practices) |
Summary
The nicotine-psychosis relationship is bidirectional and mechanistically rich. People with psychosis smoke heavily, likely because nicotine temporarily corrects dopaminergic and cholinergic deficits underlying their symptoms. At the same time, chronic nicotine/tobacco exposure causes serious physical health harms, dangerous drug interactions with antipsychotics via CYP1A2 induction, and may contribute causally to psychosis development. Clinically, switching to vaping is often the most practical harm-reduction step, while abrupt cessation requires careful antipsychotic dose monitoring.
Recent evidence to note: A 2024 meta-analysis PMID 39353226 examined the effects of acute smoking abstinence in schizophrenia patients, confirming cognitive and mood worsening during nicotine withdrawal - supporting the difficulty of cessation in this population.
This is a shared conversation. Sign in to Orris to start your own chat.